The Council of Ministers today agreed to authorise the third Agreement of the European Commission for the acquisition of Pfizer / BioNtech vaccines against COVID-19, thanks to which Spain will receive about 94 million doses for the 2022 and 2023 campaigns.
On May 7, the European Commission reached an agreement to acquire 900 million new doses of vaccine against COVID-19 with the pharmaceutical company Pfizer / BioNTech. This is the third acquisition agreement with this company and is intended for the vaccination campaigns of 2022 and 2023.
Specifically, Spain will receive 93,960,000 doses, 10.44% of the total, as has been established according to the population quota. Deliveries will be made in three tranches: 6,264,000 in December 2021, 40,716,000 between January and June 2022; and 46,980,000 between January and June 2023.
In each annual vaccination campaign, the European Union will purchase 450 million doses. In addition, the agreement includes the possibility of acquiring an additional 900 million in tranches of 150 million. This includes not only the vaccine as it is currently formulated but also possible alternative formulations. In the same way, it also contemplates the priority right to the delivery of vaccines adapted to variants from January 2022.
The agreement also provides that Member States can resell the purchased doses, non-profit, or donate them to low- or middle-income countries or public institutions.